Articles published by Pfizer Inc.
![](https://mms.businesswire.com/media/20230525005684/en/1045874/5/Pfizer_Logo_Color_RGB_APPROVED.jpg)
Pfizer Presents Scientific Advancements from its Leading Oncology Portfolio at ASCO 2023 Annual Meeting
May 25, 2023
From Pfizer Inc.
Via Business Wire
Tickers
PFE
![](https://mms.businesswire.com/media/20230525005573/en/1045874/5/Pfizer_Logo_Color_RGB_APPROVED.jpg)
![](https://mms.businesswire.com/media/20230518005725/en/1045874/5/Pfizer_Logo_Color_RGB_APPROVED.jpg)
![](https://mms.businesswire.com/media/20230516005960/en/1045874/5/Pfizer_Logo_Color_RGB_APPROVED.jpg)
Pfizer Prices $31,000,000,000 Debt Offering
May 16, 2023
From Pfizer Inc.
Via Business Wire
Tickers
PFE
![](https://mms.businesswire.com/media/20230514005054/en/1045874/5/Pfizer_Logo_Color_RGB_APPROVED.jpg)
Pfizer Announces Proposed Notes Offering
May 15, 2023
From Pfizer Inc.
Via Business Wire
Tickers
PFE
![](https://mms.businesswire.com/media/20230502005284/en/1045874/5/Pfizer_Logo_Color_RGB_APPROVED.jpg)
Pfizer Reports First-Quarter 2023 Results
May 02, 2023
From Pfizer Inc.
Via Business Wire
Tickers
PFE
![](https://mms.businesswire.com/media/20230426006061/en/1045874/5/Pfizer_Logo_Color_RGB_APPROVED.jpg)
U.S. FDA Approves PREVNAR 20®, Pfizer’s 20-valent Pneumococcal Conjugate Vaccine for Infants and Children
April 27, 2023
From Pfizer Inc.
Via Business Wire
Tickers
PFE
![](https://mms.businesswire.com/media/20230425006023/en/1045874/5/Pfizer_Logo_Color_RGB_APPROVED.jpg)
Pfizer Declares Second-Quarter 2023 Dividend
April 26, 2023
From Pfizer Inc.
Via Business Wire
Tickers
PFE
![](https://mms.businesswire.com/media/20230413005309/en/1045874/5/Pfizer_Logo_Color_RGB_APPROVED.jpg)
Pfizer Invites Shareholders to Attend Virtual-Only 2023 Annual Meeting of Shareholders on April 27
April 13, 2023
From Pfizer Inc.
Via Business Wire
Tickers
PFE
![](https://mms.businesswire.com/media/20230404005162/en/1045874/5/Pfizer_Logo_Color_RGB_APPROVED.jpg)
![](https://mms.businesswire.com/media/20230321005135/en/1045874/5/Pfizer_Logo_Color_RGB_APPROVED.jpg)
Pfizer Invites Public to View and Listen to Webcast of May 2 Conference Call with Analysts
March 21, 2023
From Pfizer Inc.
Via Business Wire
Tickers
PFE
![](https://mms.businesswire.com/media/20230316005635/en/1045874/5/Pfizer_Logo_Color_RGB_APPROVED.jpg)
FDA Advisory Committee Votes in Support of Favorable Benefit-Risk Profile for Pfizer’s PAXLOVID™
March 16, 2023
From Pfizer Inc.
Via Business Wire
Tickers
PFE
![](https://mms.businesswire.com/media/20230309005795/en/1045874/5/Pfizer_Logo_Color_RGB_APPROVED.jpg)
![](https://mms.businesswire.com/media/20230228005903/en/1045874/5/Pfizer_Logo_Color_RGB_APPROVED.jpg)
![](https://mms.businesswire.com/media/20230227005078/en/1045874/5/Pfizer_Logo_Color_RGB_APPROVED.jpg)
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
February 27, 2023
From Pfizer Inc.
Via Business Wire
Tickers
PFE
![](https://mms.businesswire.com/media/20230222005105/en/1045874/5/Pfizer_Logo_Color_RGB_APPROVED.jpg)
Pfizer’s Elranatamab Receives FDA and EMA Filing Acceptance
February 22, 2023
From Pfizer Inc.
Via Business Wire
Tickers
PFE
![](https://mms.businesswire.com/media/20230221005199/en/1045874/5/Pfizer_Logo_Color_RGB_APPROVED.jpg)
![](https://mms.businesswire.com/media/20230216005496/en/1045874/5/Pfizer_Logo_Color_RGB_APPROVED.jpg)
Pfizer Announces Positive TALZENNA® and XTANDI® Combination Data from Phase 3 TALAPRO-2 Study
February 16, 2023
From Pfizer Inc.
Via Business Wire
Tickers
PFE
![](https://mms.businesswire.com/media/20230216005209/en/1045874/5/Pfizer_Logo_Color_RGB_APPROVED.jpg)
Pfizer Announces The Lancet Neurology Has Published Phase 3 Data for Zavegepant for the Acute Treatment of Migraine in Adults
February 16, 2023
From Pfizer Inc.
Via Business Wire
Tickers
PFE
![](https://mms.businesswire.com/media/20230210005281/en/1045874/5/Pfizer_Logo_Color_RGB_APPROVED.jpg)
FDA Approves Pfizer's Supplemental New Drug Application for CIBINQO® (abrocitinib)
February 10, 2023
From Pfizer Inc.
Via Business Wire
Tickers
PFE
![](https://mms.businesswire.com/media/20230209005016/en/1045874/5/Pfizer_Logo_Color_RGB_APPROVED.jpg)
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
February 09, 2023
From Pfizer Inc.
Via Business Wire
Tickers
PFE
![](https://mms.businesswire.com/media/20230131005121/en/1045874/5/Pfizer_Logo_Color_RGB_APPROVED.jpg)
PFIZER REPORTS RECORD FULL-YEAR 2022 RESULTS AND PROVIDES FULL-YEAR 2023 FINANCIAL GUIDANCE
January 31, 2023
From Pfizer Inc.
Via Business Wire
Tickers
PFE
![](https://mms.businesswire.com/media/20230117005286/en/1045874/5/Pfizer_Logo_Color_RGB_APPROVED.jpg)
![](https://mms.businesswire.com/media/20230106005038/en/1045874/5/Pfizer_Logo_Color_RGB_APPROVED.jpg)
![](https://mms.businesswire.com/media/20230103005135/en/1045874/5/Pfizer_Logo_Color_RGB_APPROVED.jpg)
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
January 03, 2023
From Pfizer Inc.
Via Business Wire
Tickers
PFE
![](https://mms.businesswire.com/media/20221229005024/en/1045874/5/Pfizer_Logo_Color_RGB_APPROVED.jpg)
Pfizer Announces Positive Top-Line Results from Phase 3 Study of Hemophilia B Gene Therapy Candidate
December 29, 2022
From Pfizer Inc.
Via Business Wire
Tickers
PFE
![](https://mms.businesswire.com/media/20221228005064/en/1045874/5/Pfizer_Logo_Color_RGB_APPROVED.jpg)
![](https://mms.businesswire.com/media/20230104005006/en/1045874/5/Pfizer_Logo_Color_RGB_APPROVED.jpg)
Pfizer Announces FDA and EMA Acceptance of Etrasimod Regulatory Submissions for Ulcerative Colitis
December 21, 2022
From Pfizer Inc.
Via Business Wire
Tickers
PFE
![](https://mms.businesswire.com/media/20221220005212/en/1045874/5/Pfizer_Logo_Color_RGB_APPROVED.jpg)
Pfizer Invites Public to View and Listen to Webcast of January 31 Conference Call with Analysts
December 20, 2022
From Pfizer Inc.
Via Business Wire
Tickers
PFE
![](https://mms.businesswire.com/media/20221210005032/en/1045874/5/Pfizer_Logo_Color_RGB_APPROVED.jpg)
Pfizer Presents Updated Favorable Elranatamab Data from Pivotal Phase 2 MagnetisMM-3 Trial
December 10, 2022
From Pfizer Inc.
Via Business Wire
Tickers
PFE
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.